共 50 条
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis
被引:158
|作者:
Miloslavsky, Eli M.
[1
]
Naden, Ray P.
[2
]
Bijlsma, Johannes W. J.
[3
]
Brogan, Paul A.
[4
]
Brown, E. Sherwood
[5
]
Brunetta, Paul
[6
]
Buttgereit, Frank
[7
]
Choi, Hyon K.
[8
]
DiCaire, Jean-Francois
[9
]
Gelfand, Jeffrey M.
[10
]
Heaney, Liam G.
[11
]
Lightstone, Liz
[12
]
Lu, Na
[13
]
Murrell, Dedee F.
[14
]
Petri, Michelle
[15
]
Rosenbaum, James T.
[16
]
Saag, Kenneth S.
[17
]
Urowitz, Murray B.
[18
]
Winthrop, Kevin L.
[19
]
Stone, John H.
[20
]
机构:
[1] Massachusetts Gen Hosp, Rheumatol Allergy & Immunol Div, Boston, MA USA
[2] McMaster Univ, Fac Hlth Sci, Maternal Fetal Med, Hamilton, ON, Canada
[3] UMCUtrecht, Dept Rheumatol, Utrecht, Netherlands
[4] UCL, UCL Inst Child Hlth, Inst Child Hlth, London, England
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX USA
[6] Genentech Inc, Late Stage Immunol Prod Dev, San Francisco, CA 94080 USA
[7] Charite, Dept Immunol & Rheumatol, Berlin, Germany
[8] Harvard Med Sch, Dept Rheumatol, Boston, MA USA
[9] Pinnacle Inc, Montreal, PQ, Canada
[10] Univ Calif San Francisco, San Francisco, CA 94143 USA
[11] Queens Univ Belfast, Belfast, Antrim, North Ireland
[12] Imperial Coll London, Dept Med, Div Immunol & Inflammat, Sect Renal Med & Vasc Inflammat, London, England
[13] Massachusetts Gen Hosp, Dept Rheumatol, Boston, MA 02114 USA
[14] Univ New South Wales, Sydney, NSW, Australia
[15] Johns Hopkins Univ, Dept Rheumatol, Baltimore, MD USA
[16] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA
[17] Univ Alabama Birmingham, UAB Div Clin Immunol Rheumatol, Birmingham, AL USA
[18] Univ Toronto, Lupus Clin, Toronto Western Hosp, Ctr Prognosis Studies Rheumat Dis, Toronto, ON, Canada
[19] Oregon Hlth & Sci Univ, Portland, OR USA
[20] Harvard Med Sch, Rheumatol Clin Boston, Massachusetts Gen Hosp, Rheumatol Unit, Boston, MA USA
关键词:
LOW-DOSE PREDNISOLONE;
RHEUMATOID-ARTHRITIS;
ADVERSE EVENTS;
CLASSIFICATION CRITERIA;
CONTROLLED-TRIAL;
DISEASE;
SAFETY;
DAMAGE;
D O I:
10.1136/annrheumdis-2016-210002
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objectives To develop a Glucocorticoid Toxicity Index (GTI) to assess glucocorticoid (GC)-related morbidity and GC-sparing ability of other therapies. Methods Nineteen experts on GC use and outcome measures from 11 subspecialties participated. Ten experts were from the USA; nine from Canada, Europe or Australia. Group consensus methods and multicriteria decision analysis (MCDA) were used. A Composite GTI and Specific List comprise the overall GTI. The Composite GTI reflects toxicity likely to change during a clinical trial. The Composite GTI toxicities occur commonly, vary with GC exposure, and are weighted and scored. Relative weights for items in the Composite GTI were derived by group consensus and MCDA. The Specific List is designed to capture GC toxicity not included in the Composite GTI. The Composite GTI was evaluated by application to paper cases by the investigators and an external group of 17 subspecialists. Results Thirty-one toxicity items were included in the Composite GTI and 23 in the Specific List. Composite GTI evaluation showed high inter-rater agreement (investigators. 0.88, external raters. 0.90). To assess the degree to which the Composite GTI corresponds to expert clinical judgement, participants ranked 15 cases by clinical judgement in order of highest to lowest GC toxicity. Expert rankings were then compared with case ranking by the Composite GTI, yielding excellent agreement (investigators weighted. 0.87, external raters weighted. 0.77). Conclusions We describe the development and initial evaluation of a comprehensive instrument for the assessment of GC toxicity.
引用
收藏
页码:543 / 546
页数:4
相关论文